Payers

Must biosimilar names be distinct? No, experts argue

Must biosimilar names be distinct? No, experts argue

Innovator companies want the FDA to adopt separate names for biosimilars. Manufacturing changes aren't drastic enough to make it necessary, experts argued at an FTC workshop.

What payer concerns? Sovaldi ahead of curve

What payer concerns? Sovaldi ahead of curve

By

If the HCV drug's trajectory continues, it could exceed Q1 and 2014 sales forecasts, despite payers' reported unease over price.

Obesity marketing to stay same, despite new AMA designation

Obesity marketing to stay same, despite new AMA designation

By

Drug makers say the AMA's labeling of obesity as a disease will prompt patient-physician conversations, but they have no plans to overhaul brands' messaging.

Company news: AstraZeneca, Novartis, Teva

AstaZeneca avoids a Lipitor moment, FDA approves Novartis med for Cushing's, and Teva ventures into South Korea. Plus: a closer look at health exchanges

Lilly sales dip 11% as diabetes drugs feel payer pressure

By

Price increases and belt-tightening helped prop up Eli Lilly's third quarter, but loss of formulary positioning on two key products hurt sales.

IMS pitches expanded real-world evidence platform to pharma

By

IMS has added claims data to its real-world evidence (RWE) platform, but can it satisfy industry's demand for RWE as well as a payer can?

McCann Health buys global market research consultancy

By

Double Helix, a healthcare consultancy that operates across three continents, was bought by Interpublic Group's McCann Health, the network said Monday.

Pharmas are from Mars, Payers are from Venus

By

Pharma needs to step up its sales pitch, looking beyond a drug's top attributes, to convince payers that their drugs are worth the cost.

Email Newsletters